The company will use the fresh funds to develop its fibrosis-focused pipeline. Credit: Magic mine/Shutterstock.com.

Agomab Therapeutics has secured €94.9m ($100m) in its Series C funding round to advance the development of its fibrosis-focused pipeline.

Fidelity Management & Research led the financing round, with new investors EQT Life Sciences, Canaan and Dawn Biopharma, along with current investors, taking part.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Agomab plans to use the funding proceeds to support the Phase IIa STENOVA clinical trial of its lead candidate AGMB-129 in the treatment of fibrostenosing Crohn’s disease. 

The US Food and Drug Administration granted fast-track designation for the asset. 

The fresh capital will also be used to progress and expand the company’s portfolio of anti-fibrotic and regenerative drug candidates.

See Also:

These assets include AGMB-447 for treating idiopathic pulmonary fibrosis, AGMB-101 for fibrotic disorders and AGMB-102 for degenerative disorders.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

A small molecule lung-restricted ALK5 inhibitor, AGMB-447 is set to enter a Phase I trial.

Agomab also plans to use the funds to support its strategic expansion and finance general corporate operations.

Felice Verduyn-van Weegen of EQT will join Agomab’s board, and Iyona Rajkomar of Dawn Biopharma and Colleen Cuffaro of Canaan will become board observers.

Agomab Therapeutics CEO Tim Knotnerus stated: “With the addition of these world-class investors, we continue to build the company as a leader in the field of fibrosis and have secured the funding required to conduct clinical studies for multiple drug candidates. 

“I am very pleased to be able to work with the new board to further develop our potentially game-changing therapeutics for the many patients in high need of anti-fibrotic therapies.”